These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2186412)

  • 1. Therapeutic target for cognition enhancers: diagnosis and clinical phenomenology.
    Allain H; Boyer P; Kossmann L; Lépine JP; Kanowski S
    Pharmacopsychiatry; 1990 Feb; 23 Suppl 2():49-51. PubMed ID: 2186412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-associated memory impairment and early Alzheimer's disease. Only time will tell the difference.
    Förstl H; Hentschel F; Sattel H; Geiger-Kabisch C; Besthorn C; Czech C; Mönning U; Beyreuther K
    Arzneimittelforschung; 1995 Mar; 45(3A):394-7. PubMed ID: 7763332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: an alternate hypothesis to global cognitive enhancement.
    Brousseau G; Rourke BP; Burke B
    Exp Clin Psychopharmacol; 2007 Dec; 15(6):546-54. PubMed ID: 18179307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late clinical testing of cognition enhancers: demonstration of efficacy.
    Schwartz G; Bisserbe JC; Bradford D; Sennef C; Hollister L
    Pharmacopsychiatry; 1990 Feb; 23 Suppl 2():60-2; discussion 63-4. PubMed ID: 2186415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Alzheimer drugs for mild cognitive impairment].
    Fellgiebel A
    Neuropsychiatr; 2007; 21(3):230-3. PubMed ID: 17915184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamatergic approaches to the treatment of cognitive and behavioural symptoms of Alzheimer's disease.
    Francis PT
    Neurodegener Dis; 2008; 5(3-4):241-3. PubMed ID: 18322401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].
    Robert PH; Schuck S; Dubois B; Lépine JP; Gallarda T; Olié JP; Goni S; Troy S
    Encephale; 2003; 29(3 Pt 1):266-72. PubMed ID: 12876552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is antidepressant treatment associated with reduced cognitive decline in Alzheimer's disease?
    Mossello E; Boncinelli M; Caleri V; Cavallini MC; Palermo E; Di Bari M; Tilli S; Sarcone E; Simoni D; Biagini CA; Masotti G; Marchionni N
    Dement Geriatr Cogn Disord; 2008; 25(4):372-9. PubMed ID: 18354253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple cognitive deficits during the transition to Alzheimer's disease.
    Bäckman L; Jones S; Berger AK; Laukka EJ; Small BJ
    J Intern Med; 2004 Sep; 256(3):195-204. PubMed ID: 15324363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mild cognitive impairment as predictor for Alzheimer's disease in clinical practice: effect of age and diagnostic criteria.
    Visser PJ; Verhey FR
    Psychol Med; 2008 Jan; 38(1):113-22. PubMed ID: 17451628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Memory complaints in 200 subjects meeting the diagnostic criteria for age-associated memory impairment: psychoaffective and cognitive correlates].
    Derouesné C; Rapin JR; Lacomblez L
    Psychol Neuropsychiatr Vieil; 2004 Mar; 2(1):67-74. PubMed ID: 15683970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early clinical testing of cognition enhancers: prediction of efficacy.
    Hall ST; Puech A; Schaffler K; Wesnes K; Gamzu ER
    Pharmacopsychiatry; 1990 Feb; 23 Suppl 2():57-8; discussion 59. PubMed ID: 2186414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease.
    Levey A; Lah J; Goldstein F; Steenland K; Bliwise D
    Clin Ther; 2006 Jul; 28(7):991-1001. PubMed ID: 16990077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Deficits in inhibitory processes in normal aging and patients with Alzheimer's disease: a review].
    Fournet N; Mosca C; Moreaud O
    Psychol Neuropsychiatr Vieil; 2007 Dec; 5(4):281-94. PubMed ID: 18048106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rey verbal learning test is a useful tool for differential diagnosis in the preclinical phase of Alzheimer's disease: comparison with mild cognitive impairment and normal aging.
    Estévez-González A; Kulisevsky J; Boltes A; Otermín P; García-Sánchez C
    Int J Geriatr Psychiatry; 2003 Nov; 18(11):1021-8. PubMed ID: 14618554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms.
    Amieva H; Le Goff M; Millet X; Orgogozo JM; Pérès K; Barberger-Gateau P; Jacqmin-Gadda H; Dartigues JF
    Ann Neurol; 2008 Nov; 64(5):492-8. PubMed ID: 19067364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the short test of mental status and the mini-mental state examination in mild cognitive impairment.
    Tang-Wai DF; Knopman DS; Geda YE; Edland SD; Smith GE; Ivnik RJ; Tangalos EG; Boeve BF; Petersen RC
    Arch Neurol; 2003 Dec; 60(12):1777-81. PubMed ID: 14676056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mild cognitive impairment.
    Aggarwal NT
    Panminerva Med; 2007 Dec; 49(4):183-9. PubMed ID: 18091670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapy of cognitive deficits in Alzheimer's disease and age-associated memory impairment.
    Crook T
    Psychopharmacol Bull; 1988; 24(1):31-8. PubMed ID: 3290945
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.